New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects

Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalia A. Dragomiretskaya, Aida I. Tarzimanova, Julia S. Kucherova, Valery I. Podzolkov
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	aldosterone antagonists spironolactonum antifibrotic effect chronic heart failure arterial hypertension covid-19 Medicine R
Acceso en línea:	https://doaj.org/article/e182cb868ad24da2ad9e2ac5a9fda2c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e182cb868ad24da2ad9e2ac5a9fda2c2
record_format	dspace
spelling	oai:doaj.org-article:e182cb868ad24da2ad9e2ac5a9fda2c22021-12-01T12:22:36ZNew clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects0040-36602309-534210.26442/00403660.2021.09.201016https://doaj.org/article/e182cb868ad24da2ad9e2ac5a9fda2c22021-09-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/82988/63484https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).Natalia A. DragomiretskayaAida I. TarzimanovaJulia S. KucherovaValery I. Podzolkov"Consilium Medicum" Publishing housearticlealdosterone antagonistsspironolactonumantifibrotic effectchronic heart failurearterial hypertensioncovid-19MedicineRRUТерапевтический архив, Vol 93, Iss 9, Pp 1132-1137 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	aldosterone antagonists spironolactonum antifibrotic effect chronic heart failure arterial hypertension covid-19 Medicine R
spellingShingle	aldosterone antagonists spironolactonum antifibrotic effect chronic heart failure arterial hypertension covid-19 Medicine R Natalia A. Dragomiretskaya Aida I. Tarzimanova Julia S. Kucherova Valery I. Podzolkov New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
description	Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).
format	article
author	Natalia A. Dragomiretskaya Aida I. Tarzimanova Julia S. Kucherova Valery I. Podzolkov
author_facet	Natalia A. Dragomiretskaya Aida I. Tarzimanova Julia S. Kucherova Valery I. Podzolkov
author_sort	Natalia A. Dragomiretskaya
title	New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
title_short	New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
title_full	New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
title_fullStr	New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
title_full_unstemmed	New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
title_sort	new clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/e182cb868ad24da2ad9e2ac5a9fda2c2
work_keys_str_mv	AT nataliaadragomiretskaya newclinicalopportunitiesformineralocorticoidreceptorantagonistsfocusonantifibroticeffects AT aidaitarzimanova newclinicalopportunitiesformineralocorticoidreceptorantagonistsfocusonantifibroticeffects AT juliaskucherova newclinicalopportunitiesformineralocorticoidreceptorantagonistsfocusonantifibroticeffects AT valeryipodzolkov newclinicalopportunitiesformineralocorticoidreceptorantagonistsfocusonantifibroticeffects
_version_	1718405206527442944

New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects

Ejemplares similares